Answers are grounded in this paper and cite their sources.
Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions.
No takes yet. Share an insight, caveat, or question.
Berman et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: